The results were not validated in human participants or human kidney samples, so the work identifies a candidate regulatory mechanism rather than a demonstrated treatment for diabetic kidney disease. Diabetic kidney disease is a complex microvascular complication of diabetes that can progress to end-stage renal disease. The study describes interconnected metabolic, hemodynamic, genetic, oxidative and inflammatory processes as contributors to its development and progression.

High glucose can increase reactive oxygen species, or ROS, in mesangial cells, disturbing the balance between oxidants and antioxidant defenses. Such stress can damage cellular components and promote inflammatory signaling. The mechanisms linking individual transfer RNA-derived fragments, or tRFs, to these responses remain incompletely understood, so the researchers focused on tRF-15:31, a fragment previously reported at reduced levels in mouse mesangial cells treated with transforming growth factor beta 1.

To establish the mouse model, investigators used eight-week-old male C57BL/6J mice and assigned them to four groups with five animals per group: untreated controls, mice given streptozotocin, or STZ; STZ plus tRF-15:31; and STZ plus a negative-control RNA. Diabetic kidney disease was established by administering STZ at 50 mg/kg intraperitoneally for five consecutive days. At 12 weeks of age, the researchers confirmed that the model had developed, then delivered either tRF-15:31 or the negative control through a single tail-vein injection of 1 × 10^12 adeno-associated viral particles.

Kidneys and blood were collected at 20 weeks. This design tested the fragment in an intact animal model, but the small group size and use of only one sex and one strain limit how broadly the result can be generalized. In the untreated and STZ comparison, the diabetic mice had more 24-hour urinary protein and higher serum creatinine, two measured indicators of kidney function.

Periodic acid-Schiff staining showed greater glycogen accumulation in their glomeruli, while immunohistochemical analysis found increased tumor necrosis factor alpha, or TNF-α, and interleukin 6, or IL-6. Kidney tissue from STZ-treated mice also contained more malondialdehyde, a lipid-peroxidation product used as an oxidative-stress marker, and less glutathione, or GSH, an antioxidant. TNF-α, IL-6 and monocyte chemoattractant protein 1, or MCP-1, were elevated at the RNA or protein level, while glutathione peroxidase 4, or GPX4, was reduced.

Corresponding changes appeared in cultured mesangial cells maintained under high-glucose conditions. A mannitol control produced no significant changes in the tested inflammatory and oxidative-stress indicators, indicating that high osmolarity alone did not account for those effects. Both kidney tissue and high-glucose-treated cells had significantly lower tRF-15:31 expression.

Overexpressing tRF-15:31 in the diabetic mice produced a pattern of improvement across several outcomes. Compared with STZ-plus-negative-control animals, the treated mice had lower serum creatinine and less 24-hour urinary protein, while blood glucose did not differ significantly. Glomerular glycogen accumulation was reduced in periodic acid-Schiff-stained sections, and renal TNF-α and IL-6 staining was diminished.

The experimental group also had lower TNF-α and IL-6 messenger RNA, lower TNF-α and MCP-1 protein, and higher GPX4 protein. Serum IL-6 and TNF-α concentrations and renal MDA levels fell, whereas renal GSH rose. These are measured changes in an experimental mouse model; they do not by themselves establish that the RNA prevents kidney failure in people with diabetes.

The same broad effects were reproduced in cultured mouse mesangial cells. Investigators introduced a tRF-15:31 mimic into cells exposed to high glucose and confirmed its increased expression by reverse-transcription quantitative PCR. Compared with high-glucose cells receiving the negative control, cells receiving tRF-15:31 had lower TNF-α and IL-6 messenger RNA and lower concentrations of both cytokines in the culture supernatant.

Their MDA and ROS levels declined, GSH levels increased, TNF-α and MCP-1 protein levels fell, and GPX4 protein rose. The parallel findings in the mouse model and cell culture support a biological role for tRF-15:31 in suppressing the oxidative-stress and inflammatory response of mesangial cells under experimental high-glucose conditions. They do not show that the fragment acts identically in human mesangial cells or in the many other cell types present in a diabetic kidney.

Mechanistic experiments pointed to AATF as an important intermediary. AATF messenger RNA and protein were increased in STZ-treated mouse kidneys and in high-glucose-treated mesangial cells, but both were lower after tRF-15:31 was increased. A reciprocal test supported a functional relationship: co-transfecting cells with the tRF-15:31 mimic and an AATF expression plasmid weakened the fragment’s effects on TNF-α, IL-6, MCP-1 and GPX4.

In the other direction, knocking down AATF with small interfering RNA in high-glucose-treated cells reduced TNF-α and IL-6 messenger RNA, lowered TNF-α and MCP-1 protein, increased GPX4 protein, and reduced MDA and cytokine concentrations while preserving more GSH. The researchers then investigated how tRF-15:31 might reduce AATF expression. A computational prediction identified SFRS1 as a possible RNA-binding protein shared by tRF-15:31 and AATF, including a predicted “UGGA” binding site.

RNA immunoprecipitation showed that SFRS1-associated material contained tRF-15:31, while co-immunoprecipitation demonstrated an association between SFRS1 and AATF protein. These complementary assays support physical associations under the tested laboratory conditions, although they do not reveal the precise molecular contact. Knocking down SFRS1 reduced the stability of AATF messenger RNA in an actinomycin D transcription-block experiment.

Increasing tRF-15:31 also shortened AATF messenger RNA stability relative to the negative-control RNA. The proposed mechanism is therefore that tRF-15:31 associates with SFRS1, promotes loss of AATF messenger RNA stability, lowers AATF expression and thereby reduces oxidative stress and inflammatory signaling in mesangial cells. The study has important boundaries.

All in vivo findings came from an STZ-induced mouse model, and all in vitro experiments used a mouse mesangial-cell line, designated SV40-MES 13, under high-glucose conditions. The animal experiments included five mice per group, and the cell experiments were performed in triplicate according to the figure descriptions. The authors emphasize that diabetic kidney disease is a multifactorial disease, so the tRF-15:31–SFRS1–AATF relationship should be viewed as one component of a broader network of metabolic, inflammatory and oxidative pathways.

The evidence supports further investigation of the pathway’s biological significance, while its relevance to human diabetic kidney disease remains to be established.

Subject of Research: Experimental regulation of diabetic kidney injury by tRF-15:31 through SFRS1 and AATF

Article Title: tRF‐15:31‐Arg‐CCT‐3‐1 Improves Diabetic Kidney Disease by Reducing AATF and Alleviating Mesangial Cell Oxidative Stress and Inflammation

Article References: Ning, B., Huang, C., Liu, X., Qiao, Y., Ji, J., Shi, H., Qu, G., Zhao, Y., Gan, W., & Zhang, A. (2026). tRF‐15:31‐Arg‐CCT‐3‐1 Improves Diabetic Kidney Disease by Reducing AATF and Alleviating Mesangial Cell Oxidative Stress and Inflammation. Immunity, Inflammation and Disease, 14(10), Article e70561. https://doi.org/10.1002/iid3.70561

Image Credits: AI Generated

DOI: 10.1002/iid3.70561

Keywords: diabetic kidney disease, tRF-15:31, small non-coding RNA, mesangial cells, oxidative stress, inflammation, AATF, SFRS1, mouse model, kidney injury, Improves, Diabetic